RecruitingPhase 2Phase 3NCT06014801

Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients

Low-Intensity Versus Medium-Intensity Continuous Kidney Replacement Therapy for Critically Ill Patients (LIMIT): a Multicenter Randomized Clinical Trial


Sponsor

Jikei University School of Medicine

Enrollment

400 participants

Start Date

Oct 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dialysate fluid, Filtration replacement fluid for people with acute kidney injury requiring continuous renal replacement therapy. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDialysate fluid, Filtration replacement fluid

Dose of continuous hemodialysis and/or hemofiltration


Locations(9)

Sendai Medical Center

Sendai, Miyagi, Japan

Osaka Medical and Pharmaceutical University Hospital

Takatsuki, Osaka, Japan

University of Fukui Hospital

Fukui, Japan

Tsuchiura Kyodo General Hospital

Ibaraki, Japan

Osaka University Hospital

Osaka, Japan

Jichi Medical University Hospital

Tochigi, Japan

Jikei University Hospital

Tokyo, Japan

Keio University Hospital

Tokyo, Japan

Wakayama Medical University Hospital

Wakayama, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06014801